Medicine Faculty, Department of Gastroenterology, Dokuz Eylul University, Izmir, Turkey.
J Clin Gastroenterol. 2011 Aug;45 Suppl:S86-8. doi: 10.1097/MCG.0b013e31821fbd6f.
Irritable bowel syndrome is one of several highly prevalent functional gastrointestinal disorders (FGID) displaying symptoms of gastrointestinal dysmotility and visceral hypersensitivity. Substantial overlap of symptoms and comorbidities occur not only between irritable bowel syndrome and other FGID but also with gastrointestinal disorders that are not related to motility (eg, celiac disease and lactose intolerance) and to somatic conditions (eg, fibromyalgia and chronic fatigue syndrome). Pathogenic mechanisms common among FGIDs may include alternations in intestinal and colonic microflora. Evidence is also emerging of an interplay between gut immune cells/activity and alternations in motility, secretion, and sensation. The role of cytokine activity and inflammation is important in this regard. As recommended by Rome III, diagnostic testing should be guided by the patient's age, primary symptom characteristics, and other clinical and laboratory features. The high prevalence of coexisting conditions suggests the need to routinely assess patients for related disorders. Treatment should be based on an individualized evaluation, explanation, and reassurance.
肠易激综合征是几种高发的功能性胃肠疾病(FGID)之一,表现为胃肠道动力障碍和内脏敏感性增加的症状。肠易激综合征与其他 FGID 之间,不仅在症状和合并症方面存在大量重叠,而且在与动力无关的胃肠道疾病(如乳糜泻和乳糖不耐受)以及躯体疾病(如纤维肌痛和慢性疲劳综合征)方面也存在大量重叠。FGID 之间共同的发病机制可能包括肠道和结肠微生物群的改变。肠道免疫细胞/活性与动力、分泌和感觉的改变之间的相互作用也在不断出现。细胞因子活性和炎症的作用在这方面很重要。根据罗马 III 标准,诊断测试应根据患者的年龄、主要症状特征以及其他临床和实验室特征进行指导。共存疾病的高发表明,需要定期评估患者是否存在相关疾病。治疗应基于个体化评估、解释和保证。